Kailera Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 26, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 26, 2026
KLRA$14.24+3.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(amounts in thousands) (unaudited)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(78,865) | $(17,983) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 101 | 63 |
| Stock-based compensation expense | 3,939 | 1,523 |
| Change in fair value of preferred stock tranche right liability | - | (800) |
| Non-cash lease expense | 293 | (13) |
| Accretion of discounts on investments, net | (1,225) | - |
| Other | (19) | (7) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 42 | (2,674) |
| Non-current clinical deposits | (1,133) | - |
| Other non-current assets | 27 | (10) |
| Accounts payable | (495) | 645 |
| Accrued expenses and other current liabilities | 9,376 | 1,055 |
| Operating lease liabilities | (282) | - |
| Other non-current liabilities | (69) | - |
| Net cash used in operating activities | (68,310) | (18,201) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (48,448) | (54,440) |
| Maturities of marketable securities | 71,297 | - |
| Net cash provided by (used in) investing activities | 22,849 | (54,440) |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of stock options | 57 | - |
| Payments of deferred offering costs related to initial public offering | (3,037) | - |
| Net cash used in financing activities | (2,980) | - |
| Net decrease in cash, cash equivalents and restricted cash | (48,441) | (72,641) |
| Cash and cash equivalents and restricted cash at beginning of period | 161,028 | 175,178 |
| Cash, cash equivalents and restricted cash at end of period | $112,587 | $102,537 |
| Reconciliation of cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents | $111,826 | $101,776 |
| Restricted cash | 761 | 761 |
| Total cash, cash equivalents and restricted cash | $112,587 | $102,537 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Deferred offering costs included in accounts payable and accrued expenses | $2,123 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.